Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 8/20 | 0.58 |
| ▸ | NOS3 | P29474 | 1/20 | 0.58 |
| ▸ | NOS1 | P29475 | 1/20 | 0.58 |
| ▸ | NOS2 | P35228 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | PAM | P19021 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11629727 | 0.98 | IDO1 (0.59) | IDO1NOS3NOS1NOS2CA12 | |
| SCHEMBL3070200 | 0.85 | IDO1 (0.71) | IDO1NOS3NOS1NOS2CA12 | |
| SCHEMBL2364065 | 0.83 | IDO1 (0.69) | IDO1NOS3NOS1NOS2CA12 | |
| SCHEMBL2499860 | 0.83 | IDO1 (0.56) | IDO1NOS3NOS1NOS2CA12 | |
| SCHEMBL42484 | 0.81 | IDO1 (0.54) | IDO1NOS3NOS1NOS2CA12 | |
| SCHEMBL6790276 | 0.81 | TDP1 (0.55) | IDO1NOS3NOS1NOS2CA12 | |
| SCHEMBL28340394 | 0.81 | IDO1 (0.54) | IDO1NOS3NOS1NOS2CA12 | |
| SCHEMBL16115015 | 0.81 | IDO1 (0.54) | IDO1NOS3NOS1NOS2CA12 | |
| SCHEMBL6963636 | 0.81 | TDP1 (0.59) | IDO1NOS3NOS1NOS2CA12 | |
| SCHEMBL1397310 | 0.81 | IDO1 (0.65) | IDO1NOS3NOS1NOS2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 770 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035402-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | ZIKANI THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | claimed |
| US-12060334-B2 | 3-substituted phenazine derivatives as antimicrobial agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-13 | — | — | US | claimed |
| US-11634449-B2 | Macrolides and methods of their preparation and use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-04-25 | — | — | US | claimed |
| EP-3649135-B1 | SYNTHESIS OF HALICHONDRINS | HARVARD COLLEGE (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220332747-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-10-20 | — | — | US | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| EP-3172213-B1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | claimed |
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| US-5478928-A | Useful as antiviral agents in the treatment and prevention of AIDS | SOUTHERN RESEARCH INSTITUTE (US) | 1995-12-26 | — | — | US | claimed |
| WO-1995011685-A1 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1995-05-04 | — | — | WO | claimed |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12637463-B2 | Tricyclic kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260137806-A1 | INTERCALATING SUGAR MOLECULES | XALUD THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026107134-A1 | USE OF SMALL MOLECULE GLUTAMINASE INHIBITORS FOR TREATING AGE-RELATED DISORDERS | LEAL THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2002076400-A2 | INOSINE COMPOUNDS AND THEIR USE FOR TREATING OR PREVENTING AN INFLAMATION OR A REPERFUSION DISEASE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| CN-1365277-A | Methods of treating chronic pain using MEK inhibitors | VARNER LAMBERT CO (US) | 2002-08-21 | — | — | CN | disclosed |
| CN-1358095-A | Methods of treating chronic pain using MEK inhibitors | WARNER LAMBERT CO (US) | 2002-07-10 | — | — | CN | disclosed |
| US-4305958-A | Cysteine derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1981-12-15 | — | — | US | disclosed |
| US-4137420-A | EXPECTORANTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1979-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637463-B2 | Tricyclic kinase inhibitors and uses thereof | CDK1, CDK11A, CDK11B | IDO1 1458/4885NOS3 1712/4885NOS1 934/4885 |
| US-20260035402-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | MALT1, CCR10, CYP51A1 | IDO1 2101/4885NOS3 4036/4885NOS1 4007/4885 |
| US-20220332747-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | CYP11B2, ERG28, DHCR7 | IDO1 3560/4885NOS3 3718/4885NOS1 3552/4885 |
| US-11634449-B2 | Macrolides and methods of their preparation and use | CYP11B2, ERG28, DHCR7 | IDO1 3560/4885NOS3 3718/4885NOS1 3552/4885 |
| US-20260137806-A1 | INTERCALATING SUGAR MOLECULES | SLC2A1, SLC2A2, SLC2A4 | IDO1 4233/4885NOS3 3042/4885NOS1 2231/4885 |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | MAP3K1, MAP3K3, MAPK1 | IDO1 1347/4885NOS3 513/4885NOS1 863/4885 |
| US-12060334-B2 | 3-substituted phenazine derivatives as antimicrobial agents | ROS1, NOX4, NOX5 | IDO1 187/4885NOS3 293/4885NOS1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.